01
Bifidobacterium breve produces gamma-aminobutyric acid (GABA) through the enzyme glutamate decarboxylase. This GABA activates GABA-A receptors in the myenteric plexus, thereby reducing pain signalling.
Gut · LPB-GA-004
Lorbiotics · LPB-GA-004
Clinical DomainGastroenterologyLorbiotics IBS
Targeted relief for the millions who live with IBS discomfort daily. GABA-producing strains work directly on the gut-brain connection to ease pain and reduce cramping.
☆☆☆☆☆No reviews yet16BCFU at expiry · per dose
2Active strains
Capsule / SachetDosage form
- Capsules
- Allergen Free
- In Vitro Test
- Clinical Test
- 24 Month Stability
1
10B
The headline result
10 Billion CFU targeting 3 IBS axes simultaneously: GABA-mediated pain relief, IL-6 mucosal inflammation reduction, and bacteriocin SIBO control — uniquely combined with FOS + B3 + B6 + L-Tryptophan.
The science
Why IBS works.
IBS is a precision-formulated blend of Bifidobacterium breve and Lactobacillus plantarum with FOS prebiotic and B-vitamin cofactors, targeting the multifactorial pathophysiology of Irritable Bowel Syndrome.
Bifidobacterium breve is the only probiotic strain shown to produce GABA de novo in the gut lumen, directly activating enteric GABA-A receptors to reduce IBS-related visceral pain.
Paired with Lactobacillus plantarum, the IBS formula targets all three key IBS pathophysiological axes: visceral hypersensitivity (GABA modulation), mucosal inflammation (IL-6 reduction), and gut dysbiosis (bacteriocin-mediated SIBO suppression).
Therapeutic targets
- 01IBS pain relief through GABA-A receptor activation in the enteric nervous system
- 02Reduction of mucosal inflammation and restoration of intestinal barrier integrity
- 03Counteraction of gut dysbiosis via bacteriocin-mediated suppression of pathogenic bacteria
- 04Effective control of SIBO (Small Intestinal Bacterial Overgrowth)
- 05Restoration of intestinal barrier function by upregulating tight junction proteins
“IBS is a precision-formulated blend of Bifidobacterium breve and Lactobacillus plantarum with FOS prebiotic and B-vitamin cofactors, targeting the multifactorial pathophysiology of Irritable Bowel Syndrome.”
Lorbiotics IBS · Gastroenterology
Mechanism of action
How it works, step by step.
The documented biological pathway — exactly how each component acts inside the body.
02
Lactobacillus plantarum produces broad-spectrum bacteriocins, including plantaricin A, C, and D, which inhibit the growth and fermentation activity of pathogenic bacteria.
03
Vitamin B6 and tryptophan act as essential cofactors that enhance serotonin synthesis, supporting modulation of the gut-brain axis.
Inside the formula
Every ingredient earns its place.
The exact composition of Lorbiotics IBS — each organism and active listed at its formulated dose.
| Organism / active | Documented role | Dose |
|---|---|---|
| Bifidobacterium breve | — | 5 B CFU |
| Lactobacillus plantarum | — | 5 B CFU |
| FOS prebiotic | — | — |
| B-vitamin cofactors | B3, B6 | — |
| L-Tryptophan | — | — |
The practical bits
How to take it.
Dosage
1–2 sachets/capsules daily or as advised by physician.
In the pack
Capsule / Sachet · 60 per Pack
Synbiotic with FOS prebiotic + B3, B6 & L-Tryptophan. Store below 25 C away from direct sunlight.
Certifications
- WHO-GMP
- ISO 13485
- Allergen Free
- Clinical Test
- 24 Month Stability
Note: Not for medicinal use or for curative action. Recommended to use as food supplement only
Reviews
What people say after they've actually taken it.
—
☆☆☆☆☆No reviews yet
☆☆☆☆☆
No reviews yet
Reviews come from verified buyers only. Once customers who've purchased IBS share their experience, you'll see it here.
Evidence base
Peer-reviewed references.
Every claim on this page traces back to published literature. The full citation list for Lorbiotics IBS.
- 01Probiotical S.p.A. - BIFICOL. Clinically Tested Dossier, 2023 p.14.
- 02Moayyedi P, et al. Gut. 2010 59(3):325-32.
- 03Didari T, et al. World J Gastroenterol. 2015 21(10):3072-84.
- 04Whorwell PJ, et al. Am J Gastroenterol. 2006 101(7):1581-90.
Often paired with
